The relationship between latrepirdine and the typical neurotransmitter replacement therapy associated with AD (i.e. cholinesterase inhibition) is also unknown, although the side effect profile of latrepirdine [11] is not consistent with cholinergic stimulation [40]. The gene discussed is BCHE; the disease is Alzheimer disease.